Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Phase 1 clinical trial results presented at the 2013 ASCO meeting showed that the PARP inhibitor niraparib is active against breast cancer and high-grade ovarian cancer.
A phase III clinical trial called BRAVO is currently recruiting patients with metastatic or advanced breast cancer who have a BRCA1 or BRCA2 mutation. Participation in the BRAVO trial is restricted to patients who have responded well to prior surgery or radiation, and who may have had one or two prior chemotherapies. It will compare outcomes for patients who recieve niraparib compared with patients who receive standard chemotherapy.